Anti-Hypertensive Drugs - Pakistan

Pakistan

In Pakistan, the revenue in the Anti-Hypertensive Drugs market is estimated to reach US$20.36m by 2024.
It is anticipated that the revenue will exhibit a compound annual growth rate (CAGR 2024-2028) of 0.05%, leading to a market volume of US$20.40m by 2028.
When compared globally, United States is expected to generate the highest revenue with US$12,290.00m in 2024.
Despite a high prevalence of hypertension, access to affordable and quality anti-hypertensive drugs remains a challenge in Pakistan.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Pakistan has been experiencing a steady growth over the past few years.

Customer preferences: The preference for Anti-Hypertensive Drugs in Pakistan has been increasing due to the rising prevalence of hypertension among the population. According to recent studies, around one-third of the adult population in Pakistan is suffering from high blood pressure, which has led to an increase in the demand for Anti-Hypertensive Drugs.

Trends in the market: The Anti-Hypertensive Drugs market in Pakistan is witnessing a shift towards generic drugs due to their affordability and accessibility. The government has also been promoting the use of generic drugs to reduce the burden on the healthcare system. As a result, the market share of generic drugs has been increasing steadily.Another trend in the market is the increasing use of combination therapies. Physicians are prescribing combination drugs to manage hypertension more effectively. This has led to an increase in the demand for combination drugs in the market.

Local special circumstances: The healthcare system in Pakistan is highly fragmented, with a mix of public and private healthcare providers. The majority of the population relies on public healthcare facilities, which are often understaffed and under-resourced. This has led to a lack of awareness among the population regarding hypertension and its management. As a result, there is a need for increased awareness campaigns and education programs to improve the understanding of hypertension and its treatment.

Underlying macroeconomic factors: The pharmaceutical industry in Pakistan has been growing steadily due to the increasing population, rising disposable income, and the government's focus on improving the healthcare system. The government has also been promoting local manufacturing of drugs to reduce the dependence on imports and improve access to affordable medicines. These factors have contributed to the growth of the Anti-Hypertensive Drugs market in Pakistan.In conclusion, the Anti-Hypertensive Drugs market in Pakistan is witnessing a steady growth due to the rising prevalence of hypertension among the population. The market is shifting towards generic drugs and combination therapies, and there is a need for increased awareness and education programs to improve the understanding of hypertension and its management. The growth of the pharmaceutical industry and the government's focus on improving the healthcare system are underlying macroeconomic factors contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.